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Abstract
Backround: Western diet is characterized by an insufficient n-3 polyunsaturated fatty acid (PUFA) consumption
which is known to promote the pathogenesis of several diseases. We have previously observed that mice fed with
a diet poor in n-3 PUFA for two generations exhibit hepatic steatosis together with a decrease in body weight. The
gut microbiota contributes to the regulation of host energy metabolism, due to symbiotic relationship with
fermentable nutrients provided in the diet. In this study, we have tested the hypothesis that perturbations of the
gut microbiota contribute to the metabolic alterations occurring in mice fed a diet poor in n-3 PUFA for two
generations (n-3/- mice).
Methods: C57Bl/6J mice fed with a control or an n-3 PUFA depleted diet for two generations were supplemented
with prebiotic (inulin-type Fructooligosaccharides, FOS, 0.20 g/day/mice) during 24 days.
Results: n-3/-mice exhibited a marked drop in caecum weight, a decrease in lactobacilli and an increase in
bifidobacteria in the caecal content as compared to control mice (n-3/+ mice). Dietary supplementation with FOS
for 24 days was sufficient to increase caecal weight and bifidobacteria count in both n-3/+ and n-3/-mice.
Moreover, FOS increased lactobacilli content in n-3/-mice, whereas it decreased their level in n-3/+ mice.
Interestingly, FOS treatment promoted body weight gain in n-3/-mice by increasing energy efficiency. In addition,
FOS treatment decreased fasting glycemia and lowered the higher expression of key factors involved in the fatty
acid catabolism observed in the liver of n-3/-mice, without lessening steatosis.
Conclusions: the changes in the gut microbiota composition induced by FOS are different depending on the type
of diet. We show that FOS may promote lactobacilli and counteract the catabolic status induced by n-3 PUFA
depletion in mice, thereby contributing to restore efficient fat storage.
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Background
Dietary n-3 polyunsaturated fatty acids (PUFA) have
received considerable attention during the last decades.
Many epidemiological and clinical studies have
described the beneficial effects of these fatty acids on
cardiovascular disease [1], inflammation [2,3], insulin
sensitivity [4,5] and hypertriglyceridemia [6]. In addition,
by their ability to modulate the expression of regulatory
genes, n-3 PUFA can coordinate an upregulation of lipid
oxidation and a downregulation of lipid synthesis [6-8].
However, a decrease in n-3/n-6 PUFA ratio is
observed in western diets [9,10] and is well known to be
associated with an increased risk of cardiovascular dis-
ease and inflammation [9,11]. Moreover, studies have
described a lower level of n-3 PUFA in plasma [12,13],
in liver and in erythrocyte phospholipids [14] of obese
people and an lower n-3/n-6 PUFA ratio in the hepatic
phospholipids of patients with non alcoholic fatty liver
disease [15]. Several data have demonstrated that n-3
PUFA depleted rats exhibit some features of the
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hepatic steatosis [17], insulin resistance [18], cardiac
hypertrophy [19] and perturbation of metabolic, ionic
and functional events in pancreatic islets [18,20].
In a previous study, we have shown that mice fed with
a diet poor in n-3 PUFA during two generations (n-3/-
mice) exhibit a depletion in n-3 PUFA in both hepatic
phospholipids and triglycerides (TG) fraction [21].
Moreover, n-3 PUFA depleted mice show a decreased
body weight despite similar caloric intake, a higher fast-
ing glycemia and triglyceride accumulation (steatosis) in
the liver [21]. The hepatic mRNA content of fatty acid
synthase (FAS)-the rate-limiting enzyme for lipid synth-
esis-was decreased, whereas carnitine palmitoyl transfer-
ase 1 (CPT1) and peroxisome proliferator-activated
receptor gamma coactivator a (PGC1a)-two key factors
involved in b-oxidation-were increased, suggesting cata-
bolic alterations of the energy homeostasis in the liver
tissue of n-3 PUFA depleted mice [21].
The microbial fermentation of nutrients is an impor-
tant parameter to take into account when considering
energy balance [22,23]. Both dietary fat and fermentable
carbohydrates modulate the gut microbiota composition
and the extent of fermentation [24]. Carbohydrates that
partially or totally resist the digestion in the upper part
of the gut may be fermented by the saccharolytic colo-
nic bacteria, with consequences on host energy harvest
and storage [22,25]. Moreover, some carbohydrates exhi-
bit interesting nutritional properties, linked to their pre-
ferential use by specific types of bacteria. This is the
case of inulin-type fructans with prebiotic properties
that allow specific changes both in the composition and
or the activity of the gastrointestinal microbiota in
favour of bifidobacteria [26-28], thereby decreasing
inflammation and metabolic disorders -including steato-
sis- in obese mice [29]. An increase in total fat intake
promotes fat mass development at a higher extent in
mice with a complex gut microbiota than in germ-free
mice, suggesting a key role played by bacteria on host
energy storage [30]. Among saccharolytic bacteria, some
of them have been proposed to be involved in fat sto-
rage in certain conditions and models. The increase in
Firmicutes has been associated with an increase in fat
storage upon obesity [31,32]. Some strains of lactobacilli
have been shown to increase body weight in chicken
[33], whereas other strains rather decrease fat mass in
mice models of obesity or in humans [34]. On the other
hand, the consumption of a high fat diet profoundly
modifies mouse gut microbiota composition, leading
namely to a decrease in bifidobacteria and bacteroides
[24,35]. The effects of the qualitative modulation of
dietary fat content on gut microbiota and their
consequences on metabolic disorders remain largely
unexplored.
We have previously observed that mice born from a
mother fed a diet depleted in n-3 PUFA, and main-
tained on this type of diet for several months, exhibit
a decrease in caecal tissue and content weights, sug-
gesting a lower caecal fermentation, as compared to
mice fed a standard diet [21]. Therefore, this study
aimed at analyzing in the same model of nutritional
n-3 PUFA depletion, the relevance of gut microbiota
in the onset of metabolic disorders in n-3/- mice. For
this purpose, n-3/- or n-3/+ mice were treated during
24 days with prebiotics (FOS). Some results were
partly described in our previous article [21], only the
two groups of FOS treated mice were added in this
current study.
Materials and methods
Animals and diets
Old (aged from 33 to 35 weeks) female C57Bl/6J mice
fed a control diet (n-3/+, n = 9) or treated for two gen-
erations with a diet containing sub-minimal amount of
n-3 PUFA (n-3/-, n = 12) were housed at 22°C in an 12
h light/dark cycle and given free access to diet and
water. The control diet (n-3/+ diet: AO3, SAFE, Ville-
moison-sur-orge, France) contained the following (per-
cent w/w): protein 21, digestible carbohydrates 52
(including starch 34 and saccharose 3.8), soya oil 5, cel-
lulose 4, vitamin and mineral mixture 5 and water 12.
The n-3/- diet was obtained by the use of sunflower oil
which present a lower n-3/n-6 PUFA ratio compared
with the soya oil used for the n-3/+ diet. The n-3/- diet
contained the following (percent; w/w): protein 23,
digestible carbohydrates 62 (corn starch 36 and sacchar-
ose 26), sunflower oil 5, agar-agar 2, cellulose 2, vitamin
mixture 5 and mineral mixture 1. The n-3/n-6 ratio was
0.164 and 0.08 for the control diet and the n-3 PUFA-
depleted diet, respectively. The detailed fatty acid pat-
tern of these diets was fully described previously [18]. A
group of n-3/+ (n-3/+ FOS; n = 10) and n-3/- mice (n-
3/- FOS; n = 12) were supplemented for 24 days with
FOS (gift from Orafti; Tienen, Belgium). FOS was added
to tap water in a concentration adequate to reach an
intake of 0.2 g of FOS per day. The energy content of
the four diets is 331 kcal/100 g for n-3/+, 346 kcal/100
g for n-3/+ FOS, 385 kcal/100 g for n-3/- and 400 kcal/
100 g for n-3/- FOS.
All mouse experiments were approved by the local
animal ethics committee and the housing conditions
were as specified by the Belgian Law of November 14,
1993 on the protection of laboratory animals (agreement
n LA 1230314).
Food intake assessment
Food intake, taking into account spillage, was recorded
twice weekly during the last three weeks.
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An oral glucose tolerance test (gavage with 3 mg glu-
cose/g body weight; 66% glucose solution) was per-
formed on 6 h-fasted mice one week before the end of
the treatment. Blood glucose was determined with a glu-
cose meter (Roche diagnostic) on 3.5 μl of blood col-
lected from the tip of the tail vein, 30 min before and 0,
15, 30, 60, 90 and 120 min following glucose injection.
Insulin was measured in 5 μlo fp l a s m as a m p l e s
obtained from tail blood at -30 and 15 min using an
ELISA kit (Mercodia, Upssala, Sweden). The insulino-
g e n i ci n d e xw a sd e f i n e da st h er a t i oo ft h ed i f f e r e n c e
between plasma insulin concentrations (pM) at 0 and 15
min to the difference between blood glucose concentra-
tions (mM) at 0 and 15 min. The homeostasis model
assessment of insulin resistance was calculated as [fasted
glycemia (mM)*fasted insulinemia (μU/ml)]/22.5.
Tissue samples
At the age of 34 ± 1 weeks, mice were anaesthetized by
intra-peritoneal injection of sodium pentobarbital solu-
tion (Nembutal
®, 60 mg/kg of body weight, Sanofi Santé
Animale, Benelux, Brussels). The liver tissue was imme-
diately clamped in liquid N2 a n dk e p ta t- 8 0 ° C .C a e c a l
content and proximal colon were collected and stored at
-80°C. Liver, fat tissues (ovarian, subcutaneous, and visc-
eral), caecal content and caecal tissue were weighed.
Blood biochemical analysis
Vena cava blood samples were collected in EDTA tubes.
After centrifugation (10 min at 1500 g), plasma was
stored at -80°C. Plasma TG and cholesterol (Elitech
diagnostics, Sees, France) concentrations were measured
using kits coupling enzymatic reaction and spectropho-
tometric detection of reaction end-products.
Tissue biochemical analysis
For hepatic lipid content measurement, 100 mg of liver
tissue was homogenized in 0.9 ml of phosphate buffer
(pH 7.4). Lipids were extracted by mixing 125 μlo f
homogenate with 1 ml of 2:1 chloroform: methanol [36].
The chloroform phase was evaporated under nitrogen
flux, and the dried residue was solubilized in isopropa-
nol. TG or cholesterol were measured as previously
described for plasma samples.
Real-time quantitative PCR
Total RNA was isolated from liver tissue and proximal
colon (Roche Diagnostics Belgium, Vilvoorde). cDNA
was prepared by reverse transcription of 1 μg total RNA
using the Kit Reverse transcription System (Promega,
Leiden, The Netherlands). Real-time PCRs were per-
formed with StepOnePlus™ Real-time PCR system
(Applied Biosystems, Foster City, CA, USA) using
SYBER-Green for detection. Ribosomal protein L19
( R P L 1 9 )R N Aw a sc h o s e na sa ni n v a r i a n ts t a n d a r d .
The primers used were as follows: for RPL19, sense,
5’-GAAGGTCAAAGGGAATGTGTTCA-3’;a n t i s e n s e ,
5’-CCTTGTCTGCCTTCAGCTTGT-3’; for FAS, sense,
5’-TTCCAAGACGAAAATGATGC-3’;a n t i s e n s e ,5 ’-
AATTGTGGGATCAGGAGAGC-3’;f o rC P T 1 ,s e n s e ,
5’-AGACCGTGAGGAACTCAAACCTAT-3’;a n t i s e n s e ,
5’-TGAAGAGTCGCTCCCACT-3’;f o rp e r o x i s o m e
proliferator-activated receptor a (PPARa), sense,
5’-CAACGGCGTCGAAGACAAA-3’;a n t i s e n s e ,5 ’-
TGACGGTCTCCACGGACAT-3’;f o rP G C 1 a,s e n s e ,
5’-AGCCGTGACCACTGACAACGAG-3’;a n t i s e n s e ,
5’-GCTGCATGGTTCTGAGTGCTAAG-3’; for proglu-
cagon, sense, 5’-ATGAAGACCATTTACTTTG-3’;a n t i -
sense, 5’-CGGTTCCTCTTGGTGTTCATCAAC-3’.A l l
tissues were run in duplicate in a single 96-well reaction
plate (MicroAmp Optical, Applied Biosystems) and data
were analysed according to the 2-ΔCT method. The
identity and purity of the amplified product were
checked through analysis of the melting curve carried
out at the end of amplification.
Real-time quantitative PCR for microbial caecal content
The QIAamp DNA Stool Minikit (Qiagen) was used to
extract DNA from caecal content according to the man-
ufacturer’s instructions. The primers and probes used to
detect Bifidobacterium spp., Lactobacillus spp., and Bac-
teroides-Prevotella were based on 16S rRNA gene
sequences as described previously [37]. The PCR ampli-
fication reactions were carried out as follows; 2 min at
50°C, 10 min at 95°C, followed by 45 cycles of 15 s at
95°C and 1 min at 60°C, and detection was carried out
on a StepOnePlus™ Real-time PCR system (Applied
Biosystems, Foster City, CA, USA). Each assay was per-
formed in duplicate in the same run. The cycle thresh-
old of each sample was then compared to a standard
curve made by diluting genomic DNA (5-fold serial
dilution) from cultures of Bifidobacterium Longum, Lac-
tobacillus acidophilus and Bacteroides fragilis.C e l l
counts before DNA extraction were determined with the
Neubauer hemocytometer. To determine the sensitivity
and specificity of the assays, the PCR assays were con-
firmed by using a set of intestinal bacterial species as
controls. Primers used were as follows: Bifidobacterium,
sense, CGCGTCYGGTGTGAAAG; antisense, CCCCA-
CATCCAGCATCCA; Lactobacillus,s e n s e ,G A G G C A G -
CAGTAGGGAATCTTC; antisense, GGCCAGTTAC
TACCTCTATCCTTCTTC; Bacteroides-Prevotella,
sense, GAGAGGAAGGTCCCCCAC; antisense, CGCT
ACTTGGCTGGTTCAG. Taqman probes were as fol-
lows: BHQ-1-bifido, AACAGGATTAGATACCC; BHQ-
1-lacto, ATGGAGCAACGCCGC; Bacteroides-Prevotella,
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TAMRA [38].
Statistical analysis
Results are presented as mean ± SEM. Statistical signifi-
cance between groups was assessed by Student t-test
using GraphPad Prism version 4.00 for Windows. P
<0.05 was considered as statistically significant.
Results
Prebiotic intervention increases the caecal fermentation
and intestinal proglucagon expression in both groups of
mice but differentially modulates the gut microbiota in n-
3/- and n-3/+ mice
n-3/- mice have a low caecal tissue and content weights
compared with n-3/+ mice. FOS supplementation
increases caecal tissue and content weights in both
groups of mice (Figure 1A and 1B).
Lactic acid producing bacteria, namely bifidobacteria
and lactobacilli have been quantified in the caecal con-
tent of mice. Surprisingly, as shown in Figure 2, the bifi-
dobacteria level was higher in n-3/- mice than in n-3/+
mice. FOS supplementation in n-3/+ and n-3/- mice
lead to 9 to 30 fold higher caecal content in bifidobac-
teria, confirming the bifidogenic effect already observed
in several mice models. Lactobacilli basal level was
lower in n-3/- mice than in n-3/+ mice. FOS treatment
decreased the content of lactobacilli in n-3/+ mice
whereas it increased the lactobacilli in n-3/- mice (Fig-
ure 2B). The level of Bacteroides-Prevotella,a ni m p o r -
tant family of gram negative bacteria, was slightly (1.5
fold) lower in n-3/-mice than in n-3/+ mice. FOS treat-
ment promoted bacteroides in n-3/+ mice but has no
effect in n-3/- mice (Figure 2C).
The prebiotic effect of FOS is reflected through its
capacity to increase the expression of proglucagon gene
in the colon [39].
The beneficial effects of FOS supplementation on the
improvement of glucose metabolism are partly linked to
an increased production of glucagon-like peptide-1 [40].
This peptide is produced through post-translational
modification of the proglucagon mRNA. Proglucagon
mRNA content in the proximal colon was lower in n-
3/- than in n-3/+ mice. As expected, FOS supplementa-
tion increased proglucagon mRNA content in both
groups of mice, leading to a nearly two-fold increase in
proglucagon mRNA expression in n-3/- mice (Figure 3).
Prebiotic intervention increases body weight gain and
energy efficiency in n-3/- and n-3/+ mice
Body weight evolution during the follow-up was differ-
ent in n-3/- mice and in n-3/+ mice (data not shown).
FOS supplementation increased body weight gain in n-
3/- mice. n-3/- FOS mice exhibited the higher body
weight gain compared with the three other groups
(Table 1).
Energy intake during the treatment was similar
between groups. However, the energy efficiency, calcu-
lated as the ratio between body weight gain and energy
intake during the treatment, was higher in n-3/- mice
compared with n-3/+ mice. FOS supplementation
increased energy efficiency in n-3/- mice. As observed
for the body weight gain, n-3/- FOS mice exhibited the
higher energy efficiency compared with the other groups
(Table 1).
No significant modification in total adipose tissue
weights was observed between groups However, we
observed the highest visceral and subcutaneous fat mass
in n-3/- FOS mice (Table 2).
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Figure 1 Caecal content and tissue weight. (A) caecal tissue weight (g/100 g body weight), (B) caecal content weight (g). Data are the mean
± SEM. *: mean values significantly different (P < 0.05, Student’s t-test). n-3/+: mice fed with a control diet (n = 9), n-3/+ FOS: mice fed a control
diet and supplemented with a prebiotic for 24 days (n = 10), n-3/-: mice fed an n-3 PUFA-depleted diet (n = 12), n-3/- FOS: mice fed an n-3
PUFA-depleted diet and supplemented with a prebiotic for 24 days (n = 12). The results have been partly reported in reference 20.
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Page 4 of 11Prebiotic intervention inverts fatty acid catabolism in the
liver of n-3/- mice, without lessening hepatic TG
accumulation
The liver weight was higher in n-3/+ mice compared
with n-3/+ FOS and n-3/- mice (Table 3). n-3/- mice
exhibited hepatic TG accumulation (Table 3), which
mainly consisted of macrovesicular steatosis spread in
all zones of the liver lobule, compared to n-3/+ mice
(data not shown). FOS treatment had no significant
effect on hepatic triglycerides content in either n-3/+ or
n-3/- mice (Table 3), whereas it decreases lipid vesicles
size in the liver tissue of n-3/- mice (data not shown).
The hepatic cholesterol content was similar between the
four groups (Table 3).
n-3/- mice exhibited a modified liver mRNA content
of key factors involved in lipid metabolism as com-
pared to n-3/+ mice. The expression of PGC1a,at r a n -
scription factor involved in b-oxidation, and CPT1, the
rate limiting enzyme for b-oxidation, was increased in
n-3/- mice compared with n-3/+ mice (Figure 4A and
4B). The hepatic mRNA content of PPARa,a n o t h e r
transcription factor involved in b-oxidation, tended to
be higher in n-3/- mice compared with n-3/+ mice
(Figure 4C). FOS supplementation had no effect on the
expression of PGC1a, CPT1 and PPARa in n-3/+ mice
(Figure 4A, B and 4C), whereas it reduced hepatic
mRNA level of PGC1a, CPT1 and PPARa in n-3/-
mice to values similar to the ones found in n-3/+ mice
(Figure 4A, B and 4C). n-3/- mice exhibited a lower
expression of FAS, the rate-limiting enzyme for fatty
acids synthesis, compared with n-3/+ mice, an effect
which was not significantly modified by FOS treatment
(Figure 4D).
There were no differences between groups in plasma
TG concentration (Table 3). n-3/- mice exhibited higher
plasma cholesterol concentration compared with n-3/+
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Figure 2 Microbial caecal content. (A) bifidobacterium spp., (B) lactobacillus spp., (C) bacteroides-prevotella. Bacterial quantities are expressed as
Log10 (bacterial cells/g caecal content). Data are the mean ± SEM. *: mean values significantly different (P < 0.05, Student’s t-test). -3/+: mice fed
with a control diet (n = 9), n-3/+ FOS: mice fed a control diet and supplemented with a prebiotic for 24 days (n = 10), n-3/-: mice fed an n-3
PUFA-depleted diet (n = 12), n-3/- FOS: mice fed an n-3 PUFA-depleted diet and supplemented with a prebiotic for 24 days (n = 12).
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n-3/+ or n-3/- mice (Table 3).
Prebiotic supplementation reduces fasting glycemia but
does not improve insulin response to an oral glucose
tolerance test in n-3/- mice
n-3/- mice exhibited higher fasting glycemia compared
with n-3/+ mice (Figure 5A). There was no difference
b e t w e e ng r o u p si nf a s t i n ginsulinemia, measured 30
minutes before the glucose challenge (data not shown).
After an oral glucose tolerance test, the glycemic excur-
sion and the area under the curve for glycemia were
similar in all groups (Figure 5B and 5C). However, the
level of insulin measured 15 min after the glucose load
was much higher in n-3/- mice compared with n-3/+
mice (Figure 5D) leading to an increased insulinogenic
index. FOS supplementation decreased fasting glycemia
in n-3/-mice but not in n-3/+ mice (Figure 5A). The
insulinogenic index, calculated from insulin secretion 15
minutes after the glucose load, was higher in n-3/- than
in n-3/+ mice, whereas FOS had no significant effect
(Figure 5E). The homeostasis model assessment of insu-
lin resistance suggests that FOS supplementation
improves insulin sensitivity measured in the fasting state
in n-3/- mice, even if it was not statistically significant
(p = 0.06) (Figure 5F).
Discussion
Mice fed with a diet depleted in n-3 PUFA for two gen-
erations exhibit several metabolic alterations compared
to mice fed a diet with an adequate content in n-3
PUFA. Those alterations are: a lower body weight, a
higher fasting glycemia and hepatic accumulation of tri-
glycerides leading to macrovesicular steatosis. Liver
mRNA expression of key factors involved in lipid meta-
bolism could not explain this steatosis since markers
involved in b-oxidation seemed to be promoted while
markers reflecting the lipogenic pathway decreased [21].
Some recent studies have highlighted the important
role of gut microbiota in the regulation of energy meta-
bolism [22,23]. In our previous study, a decrease in cae-
cal tissue and content weights was observed in n-3/-
mice, despite the roughly similar total content in fibre
between the two diets, which suggest a lower metabolic
activity of the gut microbiota [21]. A possible relation
between n-3 PUFA level in the diet and gut bacteria
composition has been suggested by few studies. In fact,
a study conducted in rats has described a decreased
content of bacteroides after fish oil consumption, which
is rich in long chain n-3 PUFA [41]. The inhibitory
effect of n-3 PUFA on bacteroides was confirmed by
other studies [42]. Surprisingly, in our study, n-3/- mice
presented a slight decrease in bacteroides. On the other
hand, a study carried out in fish has reported an
increase content of lactobacilli under n-3 PUFA con-
sumption and a lower content under n-6 PUFA con-
sumption [43]. Coherently, we show here in mice that
the content of lactobacilli in n-3/- mice is lower than in
n-3/+ mice. Until now, the implication of such changes
on the metabolic alterations remains unknown.
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Figure 3 Proximal colon proglucagon mRNA content.D a t aa r e
the mean ± SEM. *: mean values significantly different (P < 0.05,
Student’s t-test). -3/+: mice fed with a control diet (n = 9), n-3/+
FOS: mice fed a control diet and supplemented with a prebiotic for
24 days (n = 10), n-3/-: mice fed an n-3 PUFA-depleted diet (n =
12), n-3/- FOS: mice fed an n-3 PUFA-depleted diet and
supplemented with a prebiotic for 24 days (n = 12).
Table 1 Energy intake and energy efficiency
n-3/+ n-3/+ FOS n-3/- n-3/- FOS
Body weight gain (g) -0.634 ± 0.512 0.443 ± 0.398 1.072 ± 0.157* 1.858 ± 0.197
#
Energy intake (kcal) 968.7 ± 63.6 957.6 ± 8.1 885.6 ± 4.4 822.6 ± 14.3
Energy efficiency (g/100 kcal) 0.015 ± 0.114 0.184 ± 0.167 0.484 ± 0.071* 0.900 ± 0.093
#
Energy efficiency is calculated as the ratio between body weight gain and caloric intake during the 24 days of treatment.
Data are the mean ± SEM.
*: mean values significantly different from n-3/+ mice (P < 0.05, Student’s t-test).
#: mean values significantly different from n-3/- mice (P < 0.05, Student’s t-test).
-3/+: mice fed with a control diet (n = 9), n-3/+ FOS: mice fed a control diet and supplemented with a prebiotic for 24 days (n = 10), n-3/-: mice fed an n-3
PUFA-depleted diet (n = 12), n-3/- FOS: mice fed an n-3 PUFA-depleted diet and supplemented with a prebiotic for 24 days (n = 12).
The results have been partly reported in reference 20.
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Page 6 of 11Of note, n-3/- mice exhibited no inflammatory state
(data not shown), despite the fact that n-3 PUFA are
well known modulators of the inflammatory process
[44]. The higher bifidobacteria content observed in the
caecum of n-3/- mice could be involved in the protec-
tion against the inflammation expected under n-3 PUFA
depletion, as they have been shown to correlate inver-
sely with inflammation and endotoxaemia in mice [35].
Lactobacilli are considered as important genera of sac-
charolytic bacteria, able to promote the release of short
chain fatty acids upon fermentation and thereby to
spare energy coming from the diet [33]. We can propose
that the decrease in body weight, as well as the hepatic
catabolic state observed in n-3/- mice, could be partly
due to the lower global fermentation, estimated by the
measurement of caecum weight. The fermentation of
prebiotics FOS produces short chain fatty acids in the
caeco-colon that provides energy supply for host, with
an equivalent of 1 to 1.5 kcal per g of diet [45]. The gut
microbiota can also modulate host energy metabolism
by changing the expression of factors controlling fat sto-
rage, such as the fasting-induced adipocyte factor [22].
However, this effect does not seem to contribute to the
metabolic effect of FOS in this case, since the level of
expression of FIAF-which acts as a regulator of lipopro-
tein lipase activity- was unchanged in the visceral adi-
pose tissue or liver of mice in the different groups (data
not shown).
The restoration, by FOS feeding, of the caecal content
and the increase in lactobacilli, together with the main-
tenance of high counts of bifidobacteria, as previously
shown in other models [27,35], can contribute to
increase both energy efficiency and body weight gain. It
may also contribute to restore an adequate anabolic/
catabolic balance in n-3/- mice, since prebiotic supple-
mentation in n-3/- mice leads to a restoration of key
hepatic factors involved in the fatty acid catabolism
(CPT1, PGC1a and PPARa expression). Several studies
have reported a lower steatosis linked to a decrease in
lipogenesis in rodents under FOS supplementation
[46,47]. On the contrary, FAS expression, the key
enzyme involved in fatty acid synthesis, which is lower
in the liver of n-3/- mice, was not modified by FOS
treatment. It would suggest an improvement of global
energy homeostasis in the liver of n-3 PUFA depleted
mice supplemented with FOS.
The beneficial effects of FOS supplementation
(decrease in hyperglycemia, improvement of insulin sen-
Table 3 Liver weight, triglycerides and cholesterol content and plasma triglycerides and cholesterol concentration
n-3/+ n-3/+ FOS n-3/- n-3/- FOS
Liver weight (g/100 g body weight) 4.50 ± 0.15 3.80 ± 0.11* 3.97 ± 0.08* 3.89 ± 0.05
Hepatic triglycerides content (nmol/mg proteins) 97.6 ± 10.0 115.3 ± 11.9 159.3 ± 15.4* 176.6 ± 14.5
Hepatic cholesterol content (nmol/mg proteins) 37.1 ± 2.6 43.3 ± 1.9 42.6 ± 1.8 40.8 ± 2.2
Plasma triglycerides concentration (mM) 0.41 ± 0.4 0.34 ± 0.03 0.35 ± 0.04 0.35 ± 0.03
Plasma cholesterol concentration (mM) 1.04 ± 0.05 1.00 ± 0.02 1.49 ± 0.04* 1.37 ± 0.08
Data are the mean ± SEM.
*: mean values significantly different from n-3/+ mice (P < 0.05, Student’s t-test).
#: mean values significantly different from n-3/- mice (P < 0.05, Student’s t-test).
-3/+: mice fed with a control diet (n = 9), n-3/+ FOS: mice fed a control diet and supplemented with a prebiotic for 24 days (n = 10), n-3/-: mice fed an n-3
PUFA-depleted diet (n = 12), n-3/- FOS: mice fed an n-3 PUFA-depleted diet and supplemented with a prebiotic for 24 days (n = 12).
The results have been partly reported in reference 20.
Table 2 Adipose tissue weight
n-3/+ n-3/+ FOS n-3/- n-3/- FOS
VAT (g/100 g body weight) 0.66 ± 0.11 0.76 ± 0.06 0.66 ± 0.02 0.80 ± 0.02
#
OAT (g/100 g body weight) 0.81 ± 0.14 1.13 ± 0.07 1.02 ± 0.08 0.99 ± 0.08
SAT (g/100 g body weight) 1.21 ± 0.16 1.27 ± 0.08 1.41 ± 0.06 1.45 ± 0.12
Total AT (g/100 g body weight) 2.69 ± 0.38 3.06 ± 0.22 3.09 ± 0.13 3.17 ± 0.22
VAT; visceral adipose tissue, OAT; ovarian adipose tissue, SAT; subcutaneous adipose tissue, AT; adipose tissue
Data are the mean ± SEM.
*: mean values significantly different from n-3/+ mice (P < 0.05, Student’s t-test).
#: mean values significantly different from n-3/- mice (P < 0.05, Student’s t-test).
-3/+: mice fed with a control diet (n = 9), n-3/+ FOS: mice fed a control diet and supplemented with a prebiotic for 24 days (n = 10), n-3/-: mice fed an n-3
PUFA-depleted diet (n = 12), n-3/- FOS: mice fed an n-3 PUFA-depleted diet and supplemented with a prebiotic for 24 days (n = 12).
The results have been partly reported in reference 20.
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Page 7 of 11sitivity) in animal models of obesity are reported to be
partly linked to an increased expression of proglucagon
and production of glucagon-like peptide-1 by endocrine
L-cells present in the colon [48]. We have shown here
that n-3/- mice exhibited a lower colonic content of
proglucagon mRNA compared with n-3/+ mice, whereas
FOS supplementation, in both n-3/- and n-3/+ mice,
increased the expression of this gene. This could contri-
bute to the improvement of insulin sensitivity observed
in the fasting state in n-3/- mice.
One potential mechanism involved in the changes in
bacteria composition linked to n-3 depletion, as well as
some metabolic effects of this diet, could be the differ-
ence in the nutritional composition of the diets. It
should be noted that the n-3/- diet, used by other
authors [20,49], was richer in saccharose than the n-3/+
diet. It is however unlikely that this has an influence:
feeding rats with a diet containing 15% of saccharose
had only little effects on gut microbiota as compared to
a non supplemented diet [50]. The increased content of
saccharose in the diet could neither explained the effect
on liver triglycerides accumulation [51] and on the
higher fasting glycemia [52].
Conclusions
In conclusion, a low n-3 PUFA dietary consumption is
associated to metabolic alterat i o n st h a tt a r g e tt h el i v e r ,
leading to steatosis. This long term nutritional depletion
is associated with a decrease in global fermentation and
with modifications of gut microbiota, characterized by a
huge drop of lactobacilli and, unexpectedly, an increase
in bifidobacteria. Interestingly, a relatively short treat-
ment with prebiotics can promotes energy harvesting
and reverses the decrease in caecal lactobacilli, the
higher fasting glycemia and the higher expression of key
factors involved in hepatic fatty acid catabolism. The
relevance of gut microbiota modulation in the metabolic
disorders associated with nutritional unbalance of fatty
acids is a novel concept that merits attention in further
studies.
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expression. Data are the mean ± SEM. *: mean values significantly different (P < 0.05, Student’s t-test). -3/+: mice fed with a control diet (n =
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= 12), n-3/- FOS: mice fed an n-3 PUFA-depleted diet and supplemented with a prebiotic for 24 days (n = 12). The results have been partly
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